Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financi...((19) (712) 1797 (1109) .....)

Gain on extinguishment of

development financing

obligation - - - 31,592

Gain on sale of products 715 - 5,860 -

Net loss (60,020) (20,535) (138,826) (59,391)

Beneficial conversion

feature - (18,419) - (21,920)

Loss attributable to common

stockholders $(60,020) $(38,954) $(138,826) $(81,311)

Loss per share attributable

to common stockholders,

basic and diluted $(2.53) $(2,043.15) $(10.04) $(6,254.69)

Weighted-average common

shares used in computing

loss per share attributable

to common stockholders,

basic and diluted 23,694 19 13,829 13

JAZZ PHARMACEUTICALS, INC.

SUMMARY OF PRODUCT SALES, NET

(In thousands)

(Unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Xyrem $11,120 $8,082 $39,018 $29,049

Antizol 3,740 3,472 14,153 12,813

Cystadane (1) - 336 365 1,437

Total $14,860 $11,890 $53,536 $43,299

(1) Jazz Pharmaceuticals, Inc. sold its rights to Cystadane to an

unrelated third party in March 2007.

JAZZ PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

'/>"/>